TC Biopharm
TC Biopharm
TCBP
NASDAQ
5.57
USD
743.94%
About
TC BioPharm (Holdings) plc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies (GD-Ts) for the treatment of cancer with human efficacy data in acute myeloid leukemia. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune.
It is also developing a range of genetically modified CAR-T products for the treatment of solid cancers..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 370.3K |
| Three Month Average Volume | 1.7M |
| High Low | |
| Fifty-Two Week High | 138 USD |
| Fifty-Two Week Low | 2.1101 USD |
| Fifty-Two Week High Date | 27 Nov 2023 |
| Fifty-Two Week Low Date | 14 Aug 2024 |
| Price and Volume | |
| Current Price | 5.57 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | 22.05% |
| Thirteen Week Relative Price Change | -51.81% |
| Twenty-Six Week Relative Price Change | -61.91% |
| Fifty-Two Week Relative Price Change | -96.03% |
| Year-to-Date Relative Price Change | -85.16% |
| Price Change | |
| One Day Price Change | 4.31% |
| Thirteen Week Price Change | -48.43% |
| Twenty-Six Week Price Change | -58.12% |
| Five Day Price Change | 30.75% |
| Fifty-Two Week Price Change | -95.03% |
| Year-to-Date Price Change | -82.43% |
| Month-to-Date Price Change | -10.84% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 34.26935 USD |
| Book Value Per Share (Most Recent Quarter) | 4.43877 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 26.41845 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.93894 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -99999.99 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | -99999.99 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | -99999.99 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2509.843 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -99999.99 USD |
| Normalized (Last Fiscal Year) | -2509.843 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2509.843 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -99999.99 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2509.843 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -99999.99 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 31.42823 USD |
| Cash Per Share (Most Recent Quarter) | 4.02989 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2240.885 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 64.38% |
| EPS Change (Trailing Twelve Months) | -99,999.99% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 5 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -1,287,600 |
| Net Debt (Last Fiscal Year) | -3,232,410 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | -99,999.99% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -14,115,190 |
| Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -58.42% |
| Return on Assets (Trailing Twelve Months) | -99,999.99% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -391.64% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -187.25% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -99,999.99% |